FDA Approves First Generic of Once-Daily GLP-1 Injection to …
Dec 23, 2024 · Español. Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor ...
Research shows GLP-1 drugs are effective but complex - UChicago …
May 30, 2024 · While experts caution against overusing GLP-1RAs or viewing them as a universal cure-all for obesity, physicians and researchers agree that the drugs are highly effective for weight management and Type 2 diabetes treatment.
GLP-1 drugs protect brain health by improving neurovascular …
Oct 7, 2024 · In a recent review published in the journal Cell Metabolism, a group of authors explored how Glucagon-Like Peptide-1 receptor (GLP-1R) agonism shapes the neurovascular unit (NVU), potentially...
Science’s Breakthrough of the Year: GLP-1 agonists can blunt …
Dec 15, 2023 · Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year's discovery that these drugs can blunt obesity-associated health problems as its 2023...
GLP-1 Drug Liraglutide May Protect Against Dementia
PHILADELPHIA, July 30, 2024 — A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported today at the Alzheimer’s Association International Conference ® (AAIC ®) …
Special Report: Potential Strategies for Addressing GLP-1 and Dual …
Apr 7, 2023 · Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide emerged in late 2022 and have persisted through the first quarter of 2023 (1).
Glucagon-like peptide-1 receptor: mechanisms and advances in …
Sep 18, 2024 · We introduce recent studies that demonstrate the remarkable performance of GLP-1RAs in slowing the progression of neurodegenerative diseases, reducing inflammation, and enhancing cardiovascular...
Harvard Medical School Researcher Wins 2024 Lasker Award for …
Sep 19, 2024 · Harvard Medical School researcher Joel Habener has won the 2024 Lasker~DeBakey Clinical Medical Research Award for his discovery of glucagon-like peptide-1 (GLP-1), a molecule that has become the basis for therapies which have transformed the treatment of obesity.
GLP-1R agonist liraglutide rapidly improves insulin sensitivity in …
Jan 4, 2024 · A new study published in the journal Diabetes demonstrates that a glucagon -like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and...
GLP-1 agonists: US sees 700% increase over four years in ... - The BMJ
Jul 23, 2024 · The number of patients without diabetes but with overweight or obesity who started glucagon like peptide-1 receptor agonist (GLP-1RA) treatment in the US has risen from around 21 000 in 2019 to over 174 000 in 2023—a rise of more than 700%—a study has found. 1